Drug intelligence / Profile preview

GLPG0555

Development stage: Discontinued
Lead developer: Galapagos
Modality: Small Molecules
Administration: Oral

Overview

GLPG0555 is an orally administered small molecule drug developed by Galapagos and GSK (formerly GlaxoSmithKline) for the treatment of osteoarthritis. It was designed as a disease-modifying antirheumatic agent and functions as a protein kinase modulator, specifically inhibiting Janus kinase 1 (JAK1). The drug reached Phase 1 clinical trials but development for osteoarthritis has been discontinued. No brand or generic names have been assigned beyond its code name[1][3][7].

Targets

JAK1 (Janus kinase 1)

Beyond the preview

Go deeper on GLPG0555.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GLPG0555.

Explore the full profile